ライフサイエンスコーパス: buparlisib

1 rved for the structurally related 4 (BKM120, buparlisib).

2 Once daily oral buparlisib 100 mg was administered on a continuous 28-da

3 y assigned (1:1) to receive second-line oral buparlisib (100 mg once daily) or placebo, plus intraven

4 chnology (block size of six) to receive oral buparlisib (100 mg per day) or matching placebo starting

5 e of 6) on day 15 of cycle 1 to receive oral buparlisib (100 mg/day) or matching placebo, starting on

6 Buparlisib, a pan-PI3K inhibitor, has shown preclinical

7 Although buparlisib achieved significant brain penetration, the l

8 nuous or intermittent (five on/two off days) buparlisib administration on an every-4-week schedule.

9 Buparlisib, an oral reversible inhibitor of all class I

10 Phase III trials of buparlisib and endocrine therapy in patients with ER-pos

11 Taking buparlisib as the starting point, the balanced pan-class

12 The letrozole and buparlisib combination was safe, with reversible toxicit

13 lable class I PI3K inhibitors, pictilisib or buparlisib, display elevated CMA activity, and decreased

14 for re-operation after progression received buparlisib for 7 to 13 days before surgery to evaluate b

15 s occurred in 15 (20%) of 76 patients in the buparlisib group and 17 (22%) of 78 patients in the plac

16 vival was 4.6 months (95% CI 3.5-5.3) in the buparlisib group and 3.5 months (2.2-3.7) in the placebo

17 reported for 43 (57%) of 76 patients in the buparlisib group and 37 (47%) of 78 in the placebo group

18 e reported in 62 (82%) of 76 patients in the buparlisib group and 56 (72%) of 78 patients in the plac

19 occurred in ten (3%) of 288 patients in the buparlisib group and in six (4%) of 140 in the placebo g

20 atment-related (cardiac failure [n=1] in the buparlisib group and unknown reason [n=1] in the placebo

21 reported in 134 (23%) of 573 patients in the buparlisib group compared with 90 [16%] of 570 patients

22 reported in 64 (22%) of 288 patients in the buparlisib group versus 23 (16%) of 140 in the placebo g

23 vival was 6.8 months (95% CI 4.9-7.1) in the buparlisib group versus 4.0 months (3.1-5.2) in the plac

24 vival was 6.9 months (95% CI 6.8-7.8) in the buparlisib group versus 5.0 months (4.0-5.2) in the plac

25 most common grade 3-4 adverse events in the buparlisib group versus the placebo group were increased

26 vival was 6.8 months (95% CI 5.0-7.0) in the buparlisib group vs 4.5 months (3.3-5.0) in the placebo

27 ents (occurring in >/=10% of patients in the buparlisib group vs the placebo group) were hyperglycaem

28 Buparlisib had minimal single-agent efficacy in patients

29 f this randomised phase 2 study suggest that buparlisib in combination with paclitaxel could be an ef

30 mics, and efficacy of the pan-PI3K inhibitor buparlisib in patients with recurrent glioblastoma with

31 BKM120 (Buparlisib) is one of the most advanced phosphoinositide

32 , 432 patients were randomly assigned to the buparlisib (n=289) or placebo (n=143) groups.

33 countries were randomly assigned to receive buparlisib (n=576) or placebo plus fulvestrant (n=571).

34 PI3K pathway inhibition in tumor tissue and buparlisib pharmacokinetics in cohort 1 and 6-month prog

35 INTERPRETATION: The safety profile of buparlisib plus fulvestrant does not support its further

36 essed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in patients with advanced br

37 We evaluated the efficacy and safety of buparlisib plus fulvestrant in patients with advanced br

38 This phase Ib study evaluated buparlisib plus letrozole's safety, tolerability, and pr

39 lled and randomly assigned to receive either buparlisib plus paclitaxel (n=79) or placebo plus paclit

40 Buparlisib's maximum-tolerated dose (MTD) was 100 mg/d.

41 Nonetheless, the efficacy of buparlisib supports the rationale for the use of PI3K in

42 We assessed whether the addition of buparlisib to paclitaxel improves clinical outcomes comp

43 and pertuzumab but respond to PI3K inhibitor buparlisib (TPB).

44 ients not eligible for re-operation received buparlisib until progression or unacceptable toxicity.

45 ree survival was significantly longer in the buparlisib versus placebo group (3.9 months [95% CI 2.8-

46 ost frequent grade 3-4 adverse events in the buparlisib versus placebo group were elevated alanine am